Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
IBUPROFEN SODIUM vs ALFENTA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Non-selective inhibitor of cyclooxygenase (COX-1 and COX-2), decreasing prostaglandin synthesis, resulting in anti-inflammatory, analgesic, and antipyretic effects.
μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.
Mild to moderate pain,Primary dysmenorrhea,Osteoarthritis,Rheumatoid arthritis,Fever reduction (FDA-approved OTC use),Migraine (OTC and prescription formulations)
Induction and maintenance of anesthesia,Analgesic supplement during surgical procedures,Intravenous use for monitored anesthesia care (MAC)
200-400 mg orally every 4-6 hours, maximum 1200 mg/day; for OTC use, 200-400 mg every 6-8 hours as needed, maximum 1200 mg/day.
Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.
2.0-2.5 hours (terminal); no prolongation in mild hepatic impairment; increased in renal failure.
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours); prolonged in hepatic impairment.
Primarily hepatic via CYP2C9; major metabolites are hydroxylated and carboxylated derivatives, with subsequent glucuronidation.
Hepatic via CYP3A4 to inactive metabolites; major metabolite is desmethylalfentanil (inactive).
Renal: 90% as metabolites and conjugates, <1% unchanged; biliary/fecal: minor.
Primarily renal (urinary) elimination as metabolites; approximately 80% recovered in urine, 20% in feces.
99% bound to albumin.
Approximately 92% bound, primarily to alpha-1 acid glycoprotein and albumin.
0.15-0.3 L/kg; distribution limited by high protein binding.
0.5–1.0 L/kg; reflects moderate tissue distribution; higher Vd in neonates and elderly.
Oral: 80-100% (rapid absorption); Topical: negligible systemic bioavailability (<5%).
Intravenous: 100%; intramuscular: approximately 90%; intrathecal: approximately 10% (due to systemic absorption following spinal administration).
GFR 30-90 m L/min: no adjustment needed. GFR <30 m L/min: avoid use; if necessary, reduce dose and extend interval (e.g., 200-400 mg every 8-12 hours). Not recommended in severe renal impairment (GFR <15 m L/min).
No specific dose adjustment is recommended for renal impairment; however, alfentanil is primarily metabolized in the liver and its pharmacokinetics are not significantly altered in renal failure.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% (maximum 600 mg/day). Child-Pugh C: avoid use.
In hepatic impairment (Child-Pugh class A, B, C): Reduce dose by 50% and titrate carefully due to prolonged elimination half-life. Consider lower initial doses and extended dosing intervals.
Infants and children (≥6 months): 5-10 mg/kg per dose orally every 6-8 hours, maximum 40 mg/kg/day. For fever or pain, 5 mg/kg if temperature <102.5°F, 10 mg/kg if ≥102.5°F.
Children (1-12 years): Induction of anesthesia: 10-20 mcg/kg IV; maintenance: 5-10 mcg/kg IV or infusion 0.5-1 mcg/kg/min. For neonates and infants: Dose individualization required; titrate to effect.
Initiate at lowest effective dose (200 mg) and titrate slowly; maximum 1200 mg/day. Monitor renal function, GI bleeding risk, and drug interactions (e.g., ACE inhibitors, diuretics). Avoid chronic use if possible.
Elderly patients (>65 years): Reduce initial dose by 30-50% and administer slowly. Due to decreased clearance and increased sensitivity, lower infusion rates (e.g., 0.3-0.5 mcg/kg/min) may be needed.
None formally required for ibuprofen sodium, but NSAIDs carry increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke (especially with prolonged use or in patients with cardiovascular risk factors). NSAIDs also increase risk of serious GI adverse events including bleeding, ulceration, and perforation.
Risk of respiratory depression, particularly in elderly or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Cardiovascular risk: increased risk of thrombotic events, MI, stroke; avoid in setting of CABG surgery.,GI risk: increased risk of bleeding, ulceration, perforation; caution in patients with history of peptic ulcer disease or GI bleeding.,Renal effects: may cause renal impairment, especially in elderly, volume-depleted, or those with pre-existing renal disease.,Anaphylactoid reactions: can occur in patients without prior exposure; cross-sensitivity with aspirin.,Hepatic effects: rare severe hepatic reactions; monitor liver function.,Hypertension: can worsen blood pressure control; monitor.,Asthma: may precipitate bronchospasm in aspirin-sensitive patients.
Respiratory depression; abuse potential; hypotension; bradycardia; muscle rigidity; serotonin syndrome with concurrent serotonergic drugs; adrenal insufficiency; risk of withdrawal with prolonged use.
Hypersensitivity to ibuprofen or any NSAID,History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs,Active peptic ulcer disease or GI bleeding,Severe renal impairment (Cr Cl <30 m L/min),Severe hepatic impairment,Perioperative pain in the setting of coronary artery bypass graft (CABG) surgery,Late pregnancy (third trimester) due to risk of premature closure of ductus arteriosus
Hypersensitivity to alfentanil or any component; significant respiratory insufficiency; severe asthma; paralytic ileus; concurrent use of MAOIs (or within 14 days); acute or postoperative pain management in children (except for procedural sedation).
Avoid alcohol as it increases risk of GI bleeding. High-fat meals may slightly delay absorption but not clinically significant. St. John's Wort may reduce ibuprofen levels. No specific food restrictions.
No known interactions with food. However, grapefruit juice may increase alfentanil serum concentrations due to CYP3A4 inhibition; avoid concurrent consumption.
First trimester: Avoid; associated with increased risk of cardiac defects and gastroschisis. Second trimester: Use with caution; limited evidence of structural anomalies. Third trimester: Contraindicated; risks include premature ductus arteriosus closure, oligohydramnios, and necrotizing enterocolitis.
Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effects were observed at clinically relevant doses; however, high doses caused embryotoxicity and increased fetal mortality. Trimester-specific risks: First trimester - potential for minor malformations based on limited human data; second trimester - possible risk if used chronically; third trimester - prolonged use may lead to neonatal respiratory depression, withdrawal syndrome, or opioid dependence. Use only if benefits outweigh risks.
Excreted into breast milk in low amounts (M/P ratio approximately 0.01-0.02). Considered compatible with breastfeeding due to low infant dose, but avoid if infant has thrombocytopenia or bleeding diathesis.
Alfentanil is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.3. Estimated infant dose is <1% of maternal weight-adjusted dose, which is considered clinically insignificant. However, due to potential for neonatal opioid effects, caution is advised; monitor infant for drowsiness, respiratory depression, and feeding difficulties. Consider alternative analgesics with established safety profiles, such as acetaminophen or ibuprofen, for lactation.
No specific dose adjustment required for pharmacokinetic changes in pregnancy; however, use lowest effective dose and shortest duration. Avoid in third trimester due to fetal risks. Increased renal clearance in pregnancy may reduce efficacy, but no dosing recommendations exist.
Pregnancy can alter pharmacokinetics of alfentanil. Increased plasma volume and distribution may require higher doses to achieve same effect, while decreased plasma protein binding may increase free fraction, potentiating effects. Alpha-1-acid glycoprotein levels change in pregnancy, affecting binding. In third trimester, clearance may be increased by up to 50% due to enhanced hepatic metabolism. Therefore, dose adjustments may be needed: consider starting at low dose and titrating to effect, with close monitoring. For intravenous administration, typical adult doses (5-20 μg/kg) may need adjustments; no standard pregnancy-specific dosing exists. Use the lowest effective dose for the shortest duration. In labor, avoid high doses prior to delivery due to risk of neonatal respiratory depression.
Ibuprofen sodium is more rapidly absorbed than ibuprofen acid, leading to faster onset of analgesia (within 30 minutes). Use with caution in patients with cardiovascular disease, renal impairment, or history of GI bleeding. Avoid in late pregnancy (risk of premature ductus arteriosus closure). Monitor renal function in elderly and volume-depleted patients.
Alfentanil is a potent, rapid-onset, short-acting opioid analgesic used primarily for induction and maintenance of anesthesia. Due to its high protein binding (90%) and rapid redistribution, it has a shorter duration of action than fentanyl, making it suitable for brief, painful procedures. It undergoes hepatic metabolism via CYP3A4, so concomitant use with CYP3A4 inhibitors like ketoconazole or erythromycin can prolong its effects. Use caution in elderly or hypovolemic patients due to increased risk of hypotension. Naloxone reverses respiratory depression. Alfentanil is 5-10 times less potent than fentanyl.
Take with food or milk to reduce stomach upset.,Do not exceed recommended dose (1200 mg/day OTC) or duration (10 days for pain).,Avoid alcohol while taking ibuprofen to prevent GI irritation.,Stop and seek medical attention if signs of GI bleeding (black stools, vomit with blood) occur.,Consult doctor before use if you have high blood pressure, heart disease, kidney disease, or stomach ulcers.,Do not take with other NSAIDs or aspirin without physician approval.
This medication is given only by a healthcare professional in a hospital or surgical setting.,You may feel drowsy, dizzy, or nauseated after receiving this drug.,Report any difficulty breathing or slow heart rate to your healthcare provider immediately.,Avoid alcohol and sedatives for 24 hours after administration, as they can increase side effects.,Do not drive or operate machinery until the effects have fully worn off.
"Concomitant use of Ibuprofen (a nonsteroidal anti-inflammatory drug, NSAID) and Methylprednisolone (a systemic corticosteroid) synergistically increases the risk of gastrointestinal (GI) ulceration, bleeding, and perforation due to additive inhibition of prostaglandin synthesis and mucosal protection. Additionally, Ibuprofen may potentiate the immunosuppressive effects of Methylprednisolone, elevating infection risk. This interaction can lead to serious clinical outcomes, including acute GI hemorrhage, perforation, and impaired wound healing."
"The combination of olopatadine, an antihistamine with sedative properties, and ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), may result in additive central nervous system (CNS) depression, leading to increased sedation, dizziness, and impaired psychomotor function. Ibuprofen can inhibit the metabolism of olopatadine via competition for hepatic CYP450 enzymes, potentially elevating olopatadine plasma concentrations and prolonging its systemic effects. Clinically, patients may experience exacerbated drowsiness, reduced alertness, and increased risk of falls or accidents, especially in the elderly or those with compromised hepatic function."
"Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), can decrease the metabolism of pioglitazone, a thiazolidinedione antidiabetic agent, by inhibiting cytochrome P450 2C8 (CYP2C8) enzyme activity. This inhibition elevates plasma concentrations of pioglitazone, potentially enhancing its hypoglycemic effects and increasing the risk of adverse reactions such as edema, weight gain, and heart failure exacerbation. Clinically, concomitant use may lead to improved glycemic control but also raises concerns for dose-dependent toxicities, necessitating careful monitoring and possible dose adjustment of pioglitazone."
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about IBUPROFEN SODIUM vs ALFENTA, answered by our medical review team.
IBUPROFEN SODIUM is a NSAID that works by Non-selective inhibitor of cyclooxygenase (COX-1 and COX-2), decreasing prostaglandin synthesis, resulting in anti-inflammatory, analgesic, and antipyretic effects.. ALFENTA is a Opioid Analgesic that works by μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between IBUPROFEN SODIUM and ALFENTA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of IBUPROFEN SODIUM is: 200-400 mg orally every 4-6 hours, maximum 1200 mg/day; for OTC use, 200-400 mg every 6-8 hours as needed, maximum 1200 mg/day.. The standard adult dose of ALFENTA is: Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between IBUPROFEN SODIUM and ALFENTA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. IBUPROFEN SODIUM is classified as Category D/X. First trimester: Avoid; associated with increased risk of cardiac defects and gastroschisis. Second trimester: Use with caution; limited evidence of structural anomalies. Third tri. ALFENTA is classified as Category C. Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effect. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.